1-5 of 5
Jibin Li
Close
Sort by
Journal Articles

Novel Chemotherapy-Free Initial Treatment of Rituximab Biosimilar Plus Pegylated Interferon α-2b in Pts with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Results of the Ripple 3-Year Follow-up Study

Gao Yan, Jianqiu Wu, Yunhong Huang, Hui Zhou, Ru Feng, Fei Li, Xue-Ping Li, Xiaoxiao Wang, Bing Bai, Yu-Hua Huang, Haixia He, Liqin Ping, Yanxia He, Cheng Huang, Jibin Li, Jiaying Mao, Huiqiang Huang
Journal: Blood
Blood (2023) 142 (Supplement 1): 4411.
https://doi.org/10.1182/blood-2023-186099
Published: 2023
Journal Articles

Combination Anti-PD1 Antibody and Rituximab Followed By R-CHOP for Elderly Patients with Newly Diagnosed DLBCL: Analysis of the Phase II TREND Trial

Gao Yan, Xiaoxiao Wang, Bing Bai, Xue-Ping Li, Suxia Lin, Yanxia He, Liqin Ping, Cheng Huang, Jibin Li, Jiaying Mao, Huiqiang Huang
Journal: Blood
Blood (2022) 140 (Supplement 1): 3737–3738.
https://doi.org/10.1182/blood-2022-166936
Published: 2022
Journal Articles

Rituximab Biosimilar Combined with Pegylated Interferon α-2b in Patients with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Multicenter, Single-Arm, Phase II Study

Gao Yan, Jianqiu Wu, Yunhong Huang, Hui Zhou, Ru Feng, Li Fei, Xiaoxiao Wang, Bing Bai, Yuhua Huang, Haixia He, Liqin Ping, Yanxia He, Cheng Huang, Jibin Li, Jiaying Mao, Huiqiang Huang
Journal: Blood
Blood (2021) 138 (Supplement 1): 1359.
https://doi.org/10.1182/blood-2021-152018
Published: 2021
Journal Articles

Novel Induction Therapy for Newly Diagnosed Extranodal Natural Killer/T Cell Lymphoma (ENKTL) Treated By Anti-PD-1 Antibody Plus Histone Deacetylase Inhibitor Followed By P-GemOx Regimen

Gao Yan, Yujing Zhang, Xiaoxiao Wang, Bing Bai, Yuhua Huang, Haixia He, Liqin Ping, Yanxia He, Cheng Huang, Jibin Li, Jiaying Mao, Huiqiang Huang
Journal: Blood
Blood (2021) 138 (Supplement 1): 137.
https://doi.org/10.1182/blood-2021-147169
Published: 2021
Journal Articles

Anti-PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single-Arm, Phase Ib/II Trial (SCENT)

Yan Gao, MD PhD, Huiqiang Huang, MDPhD, Xiaoxiao Wang, Bing Bai, Liling Zhang, MD PhD, Yin Xiao, Xinxiu Liu, Wenyu Li, PhD, Wei Xu, MD PhD, Ru Feng, Yu Chen, Huijing Wu, Jibin Li, Xue Wu
Journal: Blood
Blood (2020) 136 (Supplement 1): 39–40.
https://doi.org/10.1182/blood-2020-134665
Published: 2020